Ultravist 370 injection is used to help diagnose or find problems in the brain, heart, head, blood vessels, and other parts of the body. It is an iodinated contrast agent. Contrast agents are used to create a clear picture of the different parts of the body during certain medical procedures such as CT scans and angiography.
Ultravist 370 is to be used only by or under the direct supervision of a doctor.
Ultravist 370 indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored
Ultravist 370® Injection is an iodinated contrast agent indicated for:
Intra-Arterial Procedures*
150 mg I/mL for intra-arterial digital subtraction angiography (IA-DSA)
300 mg I/mL for cerebral arteriography and peripheral arteriography
370 mg I/mL for coronary arteriography and left ventriculography, visceral angiography, and aortography
Intravenous Procedures*
240 mg I/mL for peripheral venography
300 mg I/mL for excretory urography
300 mg I/mL and 370 mg I/mL for contrast Computed Tomography (CT) of the head and body (intrathoracic, intraabdominal and retroperitoneal regions) for the evaluation of neoplastic and non-neoplastic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and of low grade or infiltrative glioma has not been demonstrated.
*For information on the concentrations and doses for the Pediatric Population.
Uses of Ultravist 370 in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
Ultravist 370 is used in diagnostic procedures such as computed tomography (CT) scans and X-ray imaging to improve the visibility of different organs in the body and thus helps in the diagnosis of any find problems in different body regions.
Ultravist 370 description
sponsored
Ultravist 370 is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the path of flow of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Available as the FDA-approved product Ultravist 370, Ultravist 370 is used in radiographic studies such as intra-arterial digital subtraction angiography (IA-DSA), cerebral and peripheral arteriography, peripheral venography, excretory urography, brain computer tomography (CT), coronary arteriography, left ventriculography, visceral angiography, and aortography.
Ultravist 370 dosage
The recommended daily intake is 2 servings/day. 2 servings a day should be consumed for at least 3 weeks to see results. Ultravist 370 tastes best if served chilled. The supplement should be shaken well.
Tube Feeding: Ultravist 370 is designed to be a supplemental source of nutrition. Patients on tube feeding can receive the benefits of Ultravist 370 by providing 2 servings (240 mL) in conjunction with a standard tube feeding formula. In a tube feeding regimen, providing 2 servings of Ultravist 370 a day is suggested to achieve the recommended level of 2 g EPA, with the remaining daily calorie requirements provided by the most appropriate standard tube feeding product.
Tube Feeding Considerations: Follow physician's instructions. Ultravist 370 may be used for supplemental nutrition.
Aseptic technique should be observed when the tube feeding delivery system is assembled and when the container is open and the tube feeding is changed. Care should be taken to avoid contamination during preparation and use.
When Ultravist 370 is gravity fed, a 10 French or larger tube is recommended because of the presence of fiber in the formula. Because lower temperatures increase the viscosity of Ultravist 370, chilled Ultravist 370 will not flow as easily through the tube. Therefore, the product should be at room temperature for tube feeding.
A pump is recommended when the tube size is 8 French or less. Flushing with 20-50 mL of water every 3-4 hrs to clear the tube of residue helps prevent clogged tubes.
Adjust flow rate according to the patient's condition and tolerance.
Fluid and electrolyte status should be monitored and additional fluid provided as required.
Ultravist 370 interactions
sponsored
Drug-Drug Interactions
In patients with renal impairment, biguanides can cause lactic acidosis. Ultravist 370 appears to increase the risk of biguanide induced lactic acidosis, possibly as a result of worsening renal function.
Patients on beta-blockers may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. Because of the risk of hypersensitivity reactions, use caution when administering iodinated contrast agents to patients taking betablockers.
Interleukins are associated with an increased prevalence of delayed hypersensitivity reactions after iodinated contrast agent administration. These reactions include fever, chills, nausea, vomiting, pruritus, rash, diarrhea, hypotension, edema, and oliguria.
Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravascular contrast agents. Administration of any intravascular contrast agent should therefore be postponed in patients who have recently received a cholecystographic contrast agent.
Do not mix other drugs with Ultravist 370.
Drug-Laboratory Test Interactions
Thyroid Function Tests
The results of protein bound iodine and radioactive iodine uptake studies, which depend on iodine estimation, will not accurately reflect thyroid function for at least 16 days following administration of iodinated contrast agents. However, thyroid function tests which do not depend on iodine estimations, for example, T3 resin uptake and total or free thyroxine (T4) assays are not affected.
Laboratory Assay of Coagulation Parameters, Fibrinolysis and Complement System
The effect of Ultravist 370 on coagulation factors in in vitro assays increased with the administered dose. Coagulation, fibrinolysis and complement activation were evaluated with standard citrated human plasma in the following assays: thrombin time, thrombin coagulase time, calcium thromboplastin time, partial thromboplastin time, plasminogen, thrombin, alpha-2 antiplasmin and factor XIIa activity. Thrombin inhibition was almost complete. Data on reversibility are not available. The thrombin time increased from approximately 20 seconds at an Ultravist 370 concentration of 10 mg I/mL, up to 100 seconds at an Ultravist 370 concentration of 70 mg I/mL.
The PTT increased from approximately 50 seconds at an Ultravist 370 concentration of 10 mg I/mL, up to approximately 100 seconds at an Ultravist 370 concentration of 70 mg I/mL. A similar increase was noted in the thrombin coagulase time. Lesser effects were noted in the calcium thromboplastin time. Coagulation time increased from 13.5 to 23 seconds at the highest Ultravist 370 concentration of 70 mg I/mL. The Hageman factor split products decreased by about 20% over the range of 10 to 70 mg I/mL of Ultravist 370. Plasminogen was relatively stable. There was no evidence of activation of fibrinolysis. The complement alternate pathway was activated. Factor B conversion increased in a dose dependent manner. The duration of these effects was not studied.
In vitrostudies with human blood showed that Ultravist 370 had a slight effect on coagulation and fibrinolysis. No Factor XIIa formation could be demonstrated. The complement alternate pathway also can be activated.
The most important adverse drug reactions in patients receiving Ultravist 370 are anaphylactoid shock, contrast induced acute kidney injury, coma, cerebral infarction, stroke, brain edema, convulsion, arrhythmia, cardiac arrest, myocardial ischemia, myocardial infarction, cardiac failure, bradycardia, cyanosis, hypotension, shock, dyspnea, pulmonary edema, respiratory insufficiency and aspiration.
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice.
The following table of incidence of reactions is based upon controlled clinical trials in which Ultravist 370 was administered to 1142 patients. This listing includes all reported adverse reactions regardless of attribution. Adverse reactions are listed by System Organ Class and in decreasing order of occurrence for rates greater than 1% in the Ultravist 370 group: see Table 3.
Table 3: ADVERSE REACTIONS REPORTED IN > 1% OF PATIENTS WHO RECEIVED Ultravist 370 IN CLINICAL TRIALS
System Organ Class
Adverse Reaction
Ultravist 370
N=1142 (%)
Nervous system disorders
Headache
46 (4)
Dysgeusia
15 (1.3)
Eye disorders
Abnormal Vision
12 (1.1)
Cardiac disorders
Chest pain
18 (1.6)
Vascular disorders
Vasodilatation
30 (2.6)
Gastrointestinal disorders
Nausea
42 (3.7)
Vomiting
22 (1.9)
Musculoskeletal and connective tissue disorders
Back pain
22 (1.9)
Renal and urinary disorders
Urinary urgency
21 (1.8)
General disorders and administration site conditions
Injection site and infusion site reactions (hemorrhage, hematoma, pain, edema, erythema, rash)
41 (3.7)
Pain
13 (1.4)
One or more adverse reactions were recorded in 273 of 1142 (24%) patients during the clinical trials, coincident with the administration of Ultravist 370 or within the defined duration of the study follow-up period (24–72 hours). Ultravist 370 is often associated with sensations of warmth and/or pain.
Serious, life-threatening and fatal reactions have been associated with the administration of iodine-containing contrast media, including Ultravist 370. In clinical trials 7/1142 patients given Ultravist 370 died 5 days or later after drug administration. Also, 10/1142 patients given Ultravist 370 had serious adverse events.
The following adverse reactions were observed in ≤ 1% of the subjects receiving Ultravist 370:
The following adverse reactions have been identified during post approval use of Ultravist 370. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Adverse reactions reported in foreign postmarketing surveillance and other trials with the use of Ultravist 370 include:
Skin and subcutaneous tissue disorders: Stevens-Johnson Syndrome, skin discoloration;
Vascular disorders:vasospasm.
Pediatrics
The overall character, quality, and severity of adverse reactions in pediatric patients are generally similar to those reported in adult patients. Additional adverse reactions reported in pediatric patients from foreign marketing surveillance or other information are: epistaxis, angioedema, migraine, joint disorder (effusion), muscle cramps, mucous membrane disorder (mucosal swelling), conjunctivitis, hypoxia, fixed eruptions, vertigo, diabetes insipidus, and brain edema.
Ultravist 370 contraindications
•
Do not administer Ultravist 370 intrathecally. Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema.
•
Preparatory dehydration (for example, prolonged fasting and the administration of a laxative) before Ultravist 370 is contraindicated in pediatric patients because of risk of acute renal failure.
Active ingredient matches for Ultravist 370:
Iopromide in Belgium, Germany, Israel, Luxembourg, New Zealand, Serbia, Uruguay.
Unit description / dosage (Manufacturer)
Price, USD
Injectable; Injection; Iopromide 76.9%
Ultravist 370 solution 77 % (Bayer Inc (Canada))
List of Ultravist 370 substitutes (brand and generic names):
Ultravist (Australia, Austria, Belgium, Bosnia & Herzegowina, Bulgaria, Canada, China, Costa Rica, Croatia (Hrvatska), Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Ethiopia, Finland, France, Georgia, Germany, Greece, Guatemala, Honduras, Hungary, Iceland, India, Israel, Italy, Latvia, Lithuania, Luxembourg, Malta, New Zealand, Nicaragua, Norway, Oman, Panama, Poland, Romania, Russian Federation, Serbia, Slovenia, South Korea, Spain, Sweden, Switzerland, Tunisia, Turkey, United States)
Ultravist 300 mg/1 mL x 100 mL (Bayer schering pharma)
Ultravist 370 mg/1 mL x 1's (Bayer schering pharma)
Ultravist 0.623 mg/1 mL x 50 mL x 10 Bottle (Bayer schering pharma)
ULTRAVIST 0.623 GM INFUSION 1 bottle / 100 ML infusion each (Bayer schering pharma)
$ 19.03
ULTRAVIST 300 MG INFUSION 1 bottle / 100 ML infusion each (Bayer schering pharma)
$ 19.03
ULTRAVIST 300 MG INFUSION 1 bottle / 50 ML infusion each (Bayer schering pharma)
$ 10.28
ULTRAVIST 300 MG INJECTION 1 vial / 20 ML injection each (Bayer schering pharma)
$ 5.45
ULTRAVIST 370 MG INFUSION 1 bottle / 100 ML infusion each (Bayer schering pharma)
$ 21.18
ULTRAVIST 370 MG INFUSION 1 bottle / 50 ML infusion each (Bayer schering pharma)
DailyMed. "IOPROMIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Ultravist 370 are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ultravist 370. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported useful
No survey data has been collected yet
1 consumer reported price estimates
Was the price you paid to purchase the drug reasonable? Did you feel it was expensive? The below mentioned numbers have been reported by ndrugs.com website users about whether the Ultravist 370 drug is expensive or inexpensive. There is a mixed opinion among users. The rating about the cost of the drug depends on factors like which brand drug the patient purchased, how effective it was for the price paid, the country or place the drug is marketed, and the economic condition of the patient. The users who feel the drug is expensive can look for an alternative brand drug or a generic drug to save the cost.
Users
%
Expensive
1
100.0%
Consumer reported time for results
No survey data has been collected yet
2 consumers reported age
Users
%
1-5
1
50.0%
46-60
1
50.0%
Consumer reviews
There are no reviews yet. Be the first to write one!
